By Steve|2024-10-11T16:12:25+13:00October 15th, 2018|Categories: All, Immunotherapy, Z-Legacy|Tags: ABC-02, ARID1A, BAP1, BAY1436032, BRAF, BRCA1/2, Chemotherapy, Cyramza, dmmr, EGFR, epigenetic, FGFR2, Gem/Cis, GENOME, HER2 amplification, IDH1, IDH1/2, immunotherapy, Kelly, KEYNOTE-158, Keytruda, Lynparza, MEK, MET, MMR, olaparib, Oncologists, ramucirumab, TAS-120, TP53, treatment, TreeTopp, VEGFR, VEGFR2|
Was this helpful? Please help us help patients succeed
From Passenger To Co-Pilot: An Initiative and a carefully choreographed process that enhances healthcare by transforming the standard-of-care into a more comprehensive ‘standard-of-response’ process. At its core are printed Patient Navigator Journals and supporting digital web-app suite, all designed to better equip and empower the patients capacity to effectively respond and survive their diagnosis. A clear, step-by-step process supported by CCF peer-trained Navigators, Coaches, Hospital Ambassadors, and a constructive peer-to-peer community, replacing chaos with calm, and overwhelm with direction.
Galvanising Collaboration: The Light Australia Green Initiative is a comprehensive annual campaign focused on raising awareness and driving engagement in bile health and cancer response. Through targeted events, such as hospital-hosted symposiums, landmark illuminations on World Cholangiocarcinoma Day, and an annual conference, the initiative unites key stakeholders to promote collaboration, education and progress in managing bile-related cancers.
BILEflow Stands on its own as a research-driven initiative focused on understanding bile composition and health. Aimed at identifying chronic precancerous conditions, thus providing preventive measures for at risk /family and patient monitoring.
Support our CCA-specific BILElink For Patients: A patient-led, AI-assisted central intelligence platform that matches patient diagnoses with patient-endorsed medical professionals, remote 2nd opinions, remote collaborations, and clinical trials by mutation type.
Cholangiocarcinoma Foundation Australia is registered as a charity with the Australian Charities and Not-for-Profits Commission (ACNC). Cholangiocarcinoma Foundation Australia has Deductible Gift Recipient (DGR) status with the Australian Tax Office. Donations over $2 or more are tax-deductible. ABN: 93 665 038 102
The Empowered Patient is uniquely positioned and equipped to understand, engage, and succeed by utilizing a process that integrates scientific advancements, evidence-based medicine, and human resilience attributes into a comprehensive response strategy.
Fully embracing the concept of an empowered patient will advance science, reshape the healthcare response, and close the unattended gap between early detection and late-stage diagnosis.